- Home
- SRG vs CDXS Comparison
SRG vs CDXS Comparison
Compare SRG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- CDXS
- Stock Information
- Founded
- SRG 2014
- CDXS 2002
- Country
- SRG United States
- CDXS United States
- Employees
- SRG N/A
- CDXS N/A
- Industry
- SRG Real Estate Investment Trusts
- CDXS Major Chemicals
- Sector
- SRG Real Estate
- CDXS Industrials
- Exchange
- SRG Nasdaq
- CDXS Nasdaq
- Market Cap
- SRG 237.7M
- CDXS 216.6M
- IPO Year
- SRG 2015
- CDXS 2010
- Fundamental
- Price
- SRG $4.06
- CDXS $2.66
- Analyst Decision
- SRG
- CDXS Buy
- Analyst Count
- SRG 0
- CDXS 2
- Target Price
- SRG N/A
- CDXS $11.00
- AVG Volume (30 Days)
- SRG 96.5K
- CDXS 547.2K
- Earning Date
- SRG 11-11-2025
- CDXS 10-30-2025
- Dividend Yield
- SRG N/A
- CDXS N/A
- EPS Growth
- SRG N/A
- CDXS N/A
- EPS
- SRG N/A
- CDXS N/A
- Revenue
- SRG $15,346,000.00
- CDXS $57,164,000.00
- Revenue This Year
- SRG N/A
- CDXS $12.88
- Revenue Next Year
- SRG N/A
- CDXS $21.64
- P/E Ratio
- SRG N/A
- CDXS N/A
- Revenue Growth
- SRG N/A
- CDXS N/A
- 52 Week Low
- SRG $2.43
- CDXS $1.90
- 52 Week High
- SRG $4.72
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- SRG 51.89
- CDXS 55.26
- Support Level
- SRG $3.88
- CDXS $2.46
- Resistance Level
- SRG $4.21
- CDXS $2.76
- Average True Range (ATR)
- SRG 0.17
- CDXS 0.16
- MACD
- SRG -0.04
- CDXS 0.02
- Stochastic Oscillator
- SRG 41.94
- CDXS 50.97
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.